📰 Double Blind News
Page 11 - Double Blind News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Double Blind. Real-time updates on events, politics, business and more.
November 3, 2022
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022. Cash and investments in...
October 21, 2022
Missy Peregrym finally returns as Maggie for a big November episode of FBI while Nina's status is unknown.
September 22, 2022
-- CK0803 are neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells -- CK0803 represents the company's fifth program to receive IND Clearance utilizing Cellenkos' proprietary CRANEtechnology HOUSTON, Sept. 22, 2022 /PRNewswire/ -- Cellenkos, Inc., a clinical stage biotech company that focuses on developing transformative cellular therapeutics for treatment of inflammatory disorders and autoimmune diseases, today announced that the U.S. Food and Drug Administrati...
September 16, 2022
The freshest cuts from Laura Cox, Taipei Houston, Chris Shiflett, Willow, Alyssa Day, Bush – and more!
August 22, 2022
WALTHAM, Mass., Aug. 22, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the
August 22, 2022
WALTHAM, Mass., Aug. 22, 2022 -- Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today... | August 22, 2022
August 4, 2022
Are you looking for a way to improve your breast health? If yes, then read this review of Total Curve and learn how it works in 2023.
July 22, 2022
Mechanic Falls musician looks back on his 'Coast to Coast' touring days.
July 8, 2022
-- Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to KRYSTEXXA with methotrexate compared to KRYSTEXXA alone -- -- Trial
June 21, 2022
SAN FRANCISCO, INDIANAPOLIS and SUZHOU, China, June 21, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and other major diseases, and Eli Lilly and Company ("Lilly", NYSE: LLY) today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Ad...